Novo Nordisk ends a Wortovy deal with Hims & Hind
The “Wegven” brand Slimming syringe is sold in the Achak pharmacy in Mitte. The “Wegven” shotgun has been available in Germany for a year.
Jens Kalaene | Image Allianz | Getty pictures
Novo Nordisk On Monday it said it ended its cooperation with Hims & Hein Due to concerns about the sales and promotion of cheaper discounts of the weight loss drug Wuchshovy.
IMS & HULS shares closed more than 34% lower on Monday, while Novo Nordisk's shares were more than 5% lower.
Novo Nordisk said in April that Wegovy would offer several telemedicine companies such as HIMS & HER to expand access to the blockbuster injection, since it is no longer a lack of supply in the USA
The end of the wording meant deferred the fact that the composition of pharmacies until May 22nd was limited by the production and sale of cheaper, unauthorized versions of the drug – with rare exceptions. Telemedicine companies have announced that patients in situations in which it is medically necessary may need personalized versions of Wegven.
But Novo Nordisk said on Monday that HIMS & HINDER “did not adhere to the law that forbids the mass sales of increased drugs under the” wrong shape “of personalization. The drug maker accused HIMS and their” deceptive “marketing, which endangers the safety of the patients.
“We expected that the efforts to improve personalization would reduce over time. When we did not see it, we had to make a choice in the name of the patient,” said Dave Moore, Executive Vice President of Novo Nordisks Executive Vice President of US, to CNBC. “We were determined all the time that patient security is our main focus.”
“Our expectation was that [Hims & Hers’] Business focus would be transferred to real, safe, approved medication, “he said. Moore said that Novo Nordisk would not result in fees by completing the collaboration
In an explanation of X, Andrew Dudum, CEO from Hims & Hers said, said the company “disappointed that the management of Novo Nordisk miserates the public”.
Dudum said in the past few weeks that the Novo Nordisk team “has increasingly put us under pressure to control clinical standards and to steer patients to Wegovy, regardless of whether it was the best for patients”. He added that HIMS & HERE protecting a role in protecting the ability of providers and patients to protect individual treatment decisions, and “do not affect the integrity of our platform in order to appease a third party or to maintain cooperation”.
He said that HIMS & Hin will continue to offer several treatments, including icers that enable providers to satisfy the individual needs of patients.
In a note on Monday, the Citi analyst Daniel Grosslight said that the end of the collaboration increases the legal risk of HIMS & HOLL “essentially”. He added that he was surprised that the partnership, when he originally announced, did not include any efforts to contain the connection efforts of the Telemealth company.
During the lack of pharmacists concluded by the Food and Drug Administration, pharmacists can legally produce versions of branded medication. They can also be manufactured on a case -by -case basis if it is medically necessary for a patient, e.g.
However, drug manufacturers and some health experts are committed to practice, especially because the FDA does not agree to drugs.
Novo Nordisk said that the brand version of Wegovy would continue to offer by telemedicine organizations that “share our commitment to a safe and effective medical treatment of patients with chronic diseases”.
Moore said that Novo Nordisk has reduced or discontinued several other mass improvement pharmacies that make and sell the word -unented degrees. He added that the company would take part “in the legal front” and with the FDA to ensure that illegal compounding decreases.
In a press release on Monday, Novo Nordisk gave an investigation to determine that the active ingredients used by foreign suppliers in China are manufactured by foreign suppliers in China. In April, the drug manufacturer also cited a report by the Brookings Institution in which it was found that a large proportion of these Chinese suppliers were never inspected by the FDA and that many who were inspected had violations of drug quality securing.
“These drugs that come to our country from sources around the world are not even allowed in the countries they have created, and it is a problem,” said Moore.
